tradingkey.logo
tradingkey.logo
Search

Regenxbio Enters Settlement And Release Agreement With Glaxosmithkline On March 18, 2026 - SEC Filing

ReutersMar 20, 2026 9:43 PM

- SEC Filing:

  • REGENXBIO INC - ENTERS SETTLEMENT AND RELEASE AGREEMENT WITH GLAXOSMITHKLINE ON MARCH 18, 2026 - SEC FILING

  • REGENXBIO INC - TO PAY $10.0 MILLION TO GLAXOSMITHKLINE FOR ALLEGED UNDERPAYMENT OF SUBLICENSE FEES - SEC FILING

  • REGENXBIO INC - SETTLEMENT AGREEMENT INCLUDES MUTUAL RELEASES OF PAST AND CERTAIN FUTURE CLAIMS - SEC FILING

  • REGENXBIO INC - TO CONTINUE TO PAY GSK AMOUNTS RECEIVED FROM SUBLICENSEES PURSUANT TO EXISTING SUBLICENSE AGREEMENTS - SEC FILING

Source text: [ID:n0001193125-26-117913]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI